OptimizeRx
OPRX
128 hedge funds and large institutions have $228M invested in OptimizeRx in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 33 increasing their positions, 54 reducing their positions, and 18 closing their positions.
4,138% more call options, than puts
Call options by funds: $16.1M | Put options by funds: $380K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
12% more capital invested
Capital invested by funds: $205M → $228M (+$23.8M)
2.76% more ownership
Funds ownership: 76.5% → 79.26% (+2.8%)
0% more funds holding
Funds holding: 128 → 128 (0)
39% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIPM
G2 Investment Partners Management
New York
|
+$6M |
| 2 |
CC
Casdin Capital
New York
|
+$4.5M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$3.2M |
| 4 |
JP Morgan Chase
New York
|
+$2.31M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Handelsbanken Fonder
Stockholm,
Sweden
|
-$4.94M |
| 2 |
Millennium Management
New York
|
-$4.43M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$2.28M |
| 4 |
Two Sigma Advisers
New York
|
-$2.09M |
| 5 |
Two Sigma Investments
New York
|
-$1.81M |
OPRX Hedge Fund Activity: Q4 2022 in Review
128 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q4 2022, worth a combined $228M — up 12% from $205M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new OPRX positions and 18 closed out — a net gain of 4 holders — while 33 added to existing stakes and 54 trimmed.
The largest buyer was G2 Investment Partners Management, adding an estimated $6M. The largest seller was Handelsbanken Fonder, cutting an estimated $4.94M.
- 128 institutional investors held OptimizeRx (OPRX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $228M of OptimizeRx stock for Q4 2022, up 12% quarter-over-quarter.
- 22 funds opened new OptimizeRx positions in Q4 2022 and 18 closed out, a net change of +4 holders.
- The largest OptimizeRx buyer in Q4 2022 was G2 Investment Partners Management, an estimated $6M added.
- The largest OptimizeRx seller in Q4 2022 was Handelsbanken Fonder, an estimated $4.94M sold.
Based on aggregated 13F filings for Q4 2022.